Last reviewed · How we verify
Insulin + semaglutide treatment
Insulin + semaglutide treatment is a Insulin + GLP-1 receptor agonist combination Small molecule drug developed by Centre Hospitalier Universitaire Dijon. It is currently in Phase 3 development for Type 2 diabetes mellitus (phase 3 combination therapy).
Insulin provides glucose control via the insulin receptor, while semaglutide activates GLP-1 receptors to enhance insulin secretion, reduce glucagon, and slow gastric emptying.
Insulin provides glucose control via the insulin receptor, while semaglutide activates GLP-1 receptors to enhance insulin secretion, reduce glucagon, and slow gastric emptying. Used for Type 2 diabetes mellitus (phase 3 combination therapy).
At a glance
| Generic name | Insulin + semaglutide treatment |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | Insulin + GLP-1 receptor agonist combination |
| Target | Insulin receptor; GLP-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
This combination leverages two complementary pathways in glucose homeostasis. Insulin directly lowers blood glucose by promoting cellular uptake and storage. Semaglutide, a GLP-1 receptor agonist, stimulates insulin secretion in response to meals, suppresses glucagon secretion, and delays gastric emptying, thereby improving postprandial glucose control and promoting weight loss. Together, they address both fasting and postprandial hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus (phase 3 combination therapy)
Common side effects
- Hypoglycemia
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Weight loss
Key clinical trials
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss (PHASE2)
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PHASE3)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2) (NA)
- GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM (PHASE4)
- Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes" (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin + semaglutide treatment CI brief — competitive landscape report
- Insulin + semaglutide treatment updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI
Frequently asked questions about Insulin + semaglutide treatment
What is Insulin + semaglutide treatment?
How does Insulin + semaglutide treatment work?
What is Insulin + semaglutide treatment used for?
Who makes Insulin + semaglutide treatment?
What drug class is Insulin + semaglutide treatment in?
What development phase is Insulin + semaglutide treatment in?
What are the side effects of Insulin + semaglutide treatment?
What does Insulin + semaglutide treatment target?
Related
- Drug class: All Insulin + GLP-1 receptor agonist combination drugs
- Target: All drugs targeting Insulin receptor; GLP-1 receptor
- Manufacturer: Centre Hospitalier Universitaire Dijon — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus (phase 3 combination therapy)
- Compare: Insulin + semaglutide treatment vs similar drugs
- Pricing: Insulin + semaglutide treatment cost, discount & access